Israel Englander Argenx Se Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Argenx Se stock. As of the latest transaction made, Millennium Management LLC holds 15,300 shares of ARGX stock, worth $9.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,300

Previous 44,700 65.77%

Holding current value

$9.61 Million

Previous $19.2 Million 56.84%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $13.9 Million - $17.7 Million	32,003 Added 41.16%	109,760 $59.5 Million
Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $18.5 Million - $23.4 Million	-51,905 Reduced 40.03%	77,757 $33.4 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $77 Million - $89.2 Million	-215,769 Reduced 62.46%	129,662 $51.1 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $47.3 Million - $70.6 Million	139,538 Added 67.77%	345,431 $131 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $8.47 Million - $9.94 Million	23,521 Added 12.9%	205,893 $80.2 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $27.7 Million - $33.5 Million	82,894 Added 83.33%	182,372 $67.9 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $1.27 Million - $1.49 Million	-3,700 Reduced 3.59%	99,478 $37.7 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $9.89 Million - $11.4 Million	28,813 Added 38.75%	103,178 $36.4 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $842,167 - $1.18 Million	-3,124 Reduced 4.03%	74,365 $28.2 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $197,707 - $272,773	777 Added 1.01%	77,489 $24.4 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $16.5 Million - $21.4 Million	60,506 Added 373.36%	76,712 $26.9 Million
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $759,625 - $902,743	-2,575 Reduced 13.71%	16,206 $4.89 Million
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $7,456 - $9,277	-29 Reduced 0.15%	18,781 $5.65 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $3.99 Million - $5.66 Million	14,881 Added 378.75%	18,810 $5.18 Million
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $12.1 Million - $15.1 Million	-48,888 Reduced 92.56%	3,929 $1.16 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $2.04 Million - $3.72 Million	15,984 Added 43.4%	52,817 $11.9 Million
Q1 2020 May 14, 2020	BUY	$108.83 - $165.23 $282,631 - $429,102	2,597 Added 7.59%	36,833 $4.85 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $8.66 Million - $13.3 Million	-81,227 Reduced 70.35%	34,236 $5.5 Million
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $11.2 Million - $14.9 Million	98,811 Added 593.39%	115,463 $13.2 Million
Q2 2019 Aug 15, 2019	SELL	$115.0 - $141.58 $4.24 Million - $5.21 Million	-36,828 Reduced 68.86%	16,652 $2.36 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $3.42 Million - $4.21 Million	29,746 Added 125.33%	53,480 $3.2 Million
Q1 2019 May 14, 2019	SELL	$98.85 - $134.59 $1.93 Million - $2.62 Million	-19,479 Reduced 45.08%	23,734 $2.96 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $3.97 Million - $6.83 Million	-62,231 Reduced 59.02%	43,213 $4.15 Million
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $14.6 Million - $18.7 Million	-193,177 Reduced 64.69%	105,444 $8 Million
Q2 2018 Aug 14, 2018	SELL	$74.84 - $100.16 $39.9 Million - $53.4 Million	-533,555 Reduced 64.12%	298,621 $24.7 Million
Q1 2018 May 15, 2018	BUY	$56.95 - $85.19 $13.5 Million - $20.2 Million	236,662 Added 39.74%	832,176 $66.9 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $13.4 Million - $37.9 Million	595,514	595,514 $37.6 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account